Cutaneous Sarcoidosis

 

 Buy Article Permissions and Reprints

Abstract

Sarcoidosis is a chronic, multisystem, inflammatory disorder of unknown etiology that is characterized by noncaseating granulomas that impair normal organ functioning. Sarcoidosis predominantly affects the lungs, but the skin is often cited as the second most frequently involved organ. Cutaneous manifestations of sarcoidosis are highly variable and ongoing research seeks to better understand the relationship between clinical morphology and disease prognosis. Skin findings in patients with sarcoidosis can be “specific,” in which sarcoidal granulomas infiltrate the skin, or they can represent a “nonspecific” reactive inflammatory process, as is seen in calcinosis cutis and erythema nodosum. Cutaneous sarcoidosis can be the initial presenting sign or develop later in the course of the disease. In some patients, the skin will be the most involved and impactful organ system and will drive therapy. In other cases, the skin will be an incidental or minor finding, but may be easily accessible for biopsy to confirm the diagnosis. There are many potential therapies for sarcoidosis, though no one therapy is universally effective.

Publication History

Article published online:
27 June 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

• References

• 1 Spagnolo P. Sarcoidosis: a critical review of history and milestones. Clin Rev Allergy Immunol 2015; 49 (01) 1-5
  CrossrefPubMedGoogle Scholar
• 2 Caesar Peter Moeller Boeck (1845-1917). Boeck's sarcoidosis. JAMA 1970; 211 (09) 1537-1538
  CrossrefPubMedGoogle Scholar
• 3 Sharma OP. Sarcoidosis: a historical perspective. Clin Dermatol 2007; 25 (03) 232-241
  CrossrefPubMedGoogle Scholar
• 4 Brito-Zerón P, Sellarés J, Bosch X. , et al. Epidemiologic patterns of disease expression in sarcoidosis: age, gender and ethnicity-related differences. Clin Exp Rheumatol 2016; 34 (03) 380-388
  PubMedGoogle Scholar
• 5 Yamaguchi M, Hosoda Y, Sasaki R, Aoki K. Epidemiological study on sarcoidosis in Japan. Recent trends in incidence and prevalence rates and changes in epidemiological features. Sarcoidosis 1989; 6 (02) 138-146
  PubMedGoogle Scholar
• 6 Morimoto T, Azuma A, Abe S. , et al. Epidemiology of sarcoidosis in Japan. Eur Respir J 2008; 31 (02) 372-379
  CrossrefPubMedGoogle Scholar
• 7 Rybicki BA, Maliarik MJ, Major M, Popovich Jr J, Iannuzzi MC. Epidemiology, demographics, and genetics of sarcoidosis. Semin Respir Infect 1998; 13 (03) 166-173
  PubMedGoogle Scholar
• 8 Baughman RP, Teirstein AS, Judson MA. , et al; Case Control Etiologic Study of Sarcoidosis (ACCESS) research group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164 (10, Pt 1): 1885-1889
  CrossrefPubMedGoogle Scholar
• 9 Yanardağ H, Pamuk ON, Karayel T. Cutaneous involvement in sarcoidosis: analysis of the features in 170 patients. Respir Med 2003; 97 (08) 978-982
  CrossrefPubMedGoogle Scholar
• 10 Mañá J, Marcoval J, Rubio M, Labori M, Fanlo M, Pujol R. Granulomatous cutaneous sarcoidosis: diagnosis, relationship to systemic disease, prognosis and treatment. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30 (04) 268-281
  PubMedGoogle Scholar
• 11 Esteves TC, Aparicio G, Ferrer B, Garcia-Patos V. Prognostic value of skin lesions in sarcoidosis: clinical and histopathological clues. Eur J Dermatol 2015; 25 (06) 556-562
  CrossrefPubMedGoogle Scholar
• 12 Ungprasert P, Wetter DA, Crowson CS, Matteson EL. Epidemiology of cutaneous sarcoidosis, 1976-2013: a population-based study from Olmsted County, Minnesota. J Eur Acad Dermatol Venereol 2016; 30 (10) 1799-1804
  CrossrefPubMedGoogle Scholar
• 13 Coquart N, Cadelis G, Tressières B, Cordel N. Epidemiology of sarcoidosis in Afro-Caribbean people: a 7-year retrospective study in Guadeloupe. Int J Dermatol 2015; 54 (02) 188-192
  CrossrefPubMedGoogle Scholar
• 14 Kaloga M, Gbéry IP, Bamba V. , et al. Epidemiological, clinical, and paraclinic aspect of cutaneous sarcoidosis in black Africans. Dermatol Res Pract 2015; 2015: 802824
  CrossrefPubMedGoogle Scholar
• 15 Judson MA. The epidemic of drug-induced sarcoidosis-like reactions: a side effect that we can live with. J Intern Med 2019 Doi: 10.1111/joim.13008 [Epub ahead of print]
  PubMedGoogle Scholar
• 16 Amber KT, Bloom R, Mrowietz U, Hertl M. TNF-α: a treatment target or cause of sarcoidosis?. J Eur Acad Dermatol Venereol 2015; 29 (11) 2104-2111
  CrossrefPubMedGoogle Scholar
• 17 Leclerc S, Myers RP, Moussalli J, Herson S, Poynard T, Benveniste O. Sarcoidosis and interferon therapy: report of five cases and review of the literature. Eur J Intern Med 2003; 14 (04) 237-243
  CrossrefPubMedGoogle Scholar
• 18 Gaughan EM. Sarcoidosis, malignancy and immune checkpoint blockade. Immunotherapy 2017; 9 (13) 1051-1053
  CrossrefPubMedGoogle Scholar
• 19 Reddy SB, Possick JD, Kluger HM, Galan A, Han D. Sarcoidosis following anti-PD-1 and anti-CTLA-4 therapy for metastatic melanoma. J Immunother 2017; 40 (08) 307-311
  CrossrefPubMedGoogle Scholar
• 20 Collins LK, Chapman MS, Carter JB, Samie FH. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer 2017; 41 (02) 125-128
  CrossrefPubMedGoogle Scholar
• 21 Lheure C, Kramkimel N, Franck N. , et al. Sarcoidosis in patients treated with vemurafenib for metastatic melanoma: a paradoxical autoimmune activation. Dermatology 2015; 231 (04) 378-384
  CrossrefPubMedGoogle Scholar
• 22 Adam A, Thomas L, Bories N. , et al. Sarcoidosis associated with vemurafenib. Br J Dermatol 2013; 169 (01) 206-208
  CrossrefPubMedGoogle Scholar
• 23 Goldstein RA, Janicki BW, Mirro J, Foellmer JW. Cell-mediated immune responses in sarcoidosis. Am Rev Respir Dis 1978; 117 (01) 55-62
  PubMedGoogle Scholar
• 24 Rybicki BA, Maliarik MJ, Poisson LM. , et al. The major histocompatibility complex gene region and sarcoidosis susceptibility in African Americans. Am J Respir Crit Care Med 2003; 167 (03) 444-449
  CrossrefPubMedGoogle Scholar
• 25 Rybicki BA, Maliarik MJ, Poisson LM, Iannuzzi MC. Sarcoidosis and granuloma genes: a family-based study in African-Americans. Eur Respir J 2004; 24 (02) 251-257
  CrossrefPubMedGoogle Scholar
• 26 Grunewald J. HLA associations and Löfgren's syndrome. Expert Rev Clin Immunol 2012; 8 (01) 55-62
  CrossrefPubMedGoogle Scholar
• 27 Fingerlin TE, Hamzeh N, Maier LA. Genetics of sarcoidosis. Clin Chest Med 2015; 36 (04) 569-584
  CrossrefPubMedGoogle Scholar
• 28 Bindoli S, Dagan A, Torres-Ruiz JJ. , et al. Sarcoidosis and autoimmunity: from genetic background to environmental factors. Isr Med Assoc J 2016; 18 (3-4): 197-202
  PubMedGoogle Scholar
• 29 Eishi Y. Etiologic aspect of sarcoidosis as an allergic endogenous infection caused by Propionibacterium acnes. BioMed Res Int 2013; 2013: 935289
  CrossrefPubMedGoogle Scholar
• 30 Oswald-Richter KA, Beachboard DC, Seeley EH. , et al. Dual analysis for mycobacteria and propionibacteria in sarcoidosis BAL. J Clin Immunol 2012; 32 (05) 1129-1140
  CrossrefPubMedGoogle Scholar
• 31 Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357 (21) 2153-2165
  CrossrefPubMedGoogle Scholar
• 32 Chen ES, Moller DR. Sarcoidosis--scientific progress and clinical challenges. Nat Rev Rheumatol 2011; 7 (08) 457-467
  CrossrefPubMedGoogle Scholar
• 33 Culver DA, Newman LS, Kavuru MS. Gene-environment interactions in sarcoidosis: challenge and opportunity. Clin Dermatol 2007; 25 (03) 267-275
  CrossrefPubMedGoogle Scholar
• 34 Sakthivel P, Bruder D. Mechanism of granuloma formation in sarcoidosis. Curr Opin Hematol 2017; 24 (01) 59-65
  CrossrefPubMedGoogle Scholar
• 35 Celada LJ, Rotsinger JE, Young A. , et al. Programmed death-1 inhibition of phosphatidylinositol 3-kinase/AKT/mechanistic target of rapamycin signaling impairs sarcoidosis CD4⁺ T cell proliferation. Am J Respir Cell Mol Biol 2017; 56 (01) 74-82
  CrossrefPubMedGoogle Scholar
• 36 Tetzlaff MT, Nelson KC, Diab A. , et al. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. J Immunother Cancer 2018; 6 (01) 14
  CrossrefPubMedGoogle Scholar
• 37 Xu J, Sun HH, Fletcher CDM. , et al. Expression of programmed cell death 1 ligands (PD-L1 and PD-L2) in histiocytic and dendritic cell disorders. Am J Surg Pathol 2016; 40 (04) 443-453
  CrossrefPubMedGoogle Scholar
• 38 Braun NA, Celada LJ, Herazo-Maya JD. , et al. Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity. Am J Respir Crit Care Med 2014; 190 (05) 560-571
  CrossrefPubMedGoogle Scholar
• 39 Marcoval J, Mañá J, Rubio M. Specific cutaneous lesions in patients with systemic sarcoidosis: relationship to severity and chronicity of disease. Clin Exp Dermatol 2011; 36 (07) 739-744
  CrossrefPubMedGoogle Scholar
• 40 Rosenbach M, Yeung H, Chu EY. , et al. Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis. JAMA Dermatol 2013; 149 (05) 550-556
  CrossrefPubMedGoogle Scholar
• 41 Yeung H, Farber S, Birnbaum BK. , et al. Reliability and validity of cutaneous sarcoidosis outcome instruments among dermatologists, pulmonologists, and rheumatologists. JAMA Dermatol 2015; 151 (12) 1317-1322
  CrossrefPubMedGoogle Scholar
• 42 Spiteri MA, Matthey F, Gordon T, Carstairs LS, James DG. Lupus pernio: a clinico-radiological study of thirty-five cases. Br J Dermatol 1985; 112 (03) 315-322
  CrossrefPubMedGoogle Scholar
• 43 Nagai Y, Igarashi N, Ishikawa O. Lupus pernio with multiple bone cysts in the fingers. J Dermatol 2010; 37 (09) 812-814
  CrossrefPubMedGoogle Scholar
• 44 Efthimiou P, Kukar M. Lupus pernio: sarcoid-specific cutaneous manifestation associated with chronic sarcoid arthropathy. J Clin Rheumatol 2011; 17 (06) 343
  CrossrefPubMedGoogle Scholar
• 45 Atci T, Baykal C, Kaya Bingöl Z, Polat Ekinci A, Kiliçaslan Z. Scar sarcoidosis: 11 patients with variable clinical features and invariable pulmonary involvement. Clin Exp Dermatol 2019; 44 (07) 826-828
  CrossrefPubMedGoogle Scholar
• 46 Martires K, Shvartsbeyn M, Brinster N, Ramachandran S, Franks Jr AG. Sarcoidosis. Dermatol Online J 2015; 21 (12) 13030/qt5d3306f8
  CrossrefPubMedGoogle Scholar
• 47 Adamson HG. Tuberculide of the type called “sarcoid” of Darier-Roussy. Proc R Soc Med 1912; 5 (Dermatol Sect): 132-133
  PubMedGoogle Scholar
• 48 Ando M, Miyazaki E, Hatano Y. , et al. Subcutaneous sarcoidosis: a clinical analysis of nine patients. Clin Rheumatol 2016; 35 (09) 2277-2281
  CrossrefPubMedGoogle Scholar
• 49 O'Neill JL, Moustafa F, Teague D, Huang WW. Subcutaneous sarcoidosis without systemic involvement. Dermatol Online J 2014; 20 (08) 13030/qt0hd858q9
  CrossrefPubMedGoogle Scholar
• 50 Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 1983; 52 (208) 525-533
  PubMedGoogle Scholar
• 51 Milman N, Selroos O. Pulmonary sarcoidosis in the Nordic countries 1950-1982. II. Course and prognosis. Sarcoidosis 1990; 7 (02) 113-118
  PubMedGoogle Scholar
• 52 Wanat KA, Rosenbach M. Cutaneous sarcoidosis. Clin Chest Med 2015; 36 (04) 685-702
  CrossrefPubMedGoogle Scholar
• 53 James DG, Thomson AD, Willcox A. Erythema nodosum as a manifestation of sarcoidosis. Lancet 1956; 271 (6936): 218-221
  CrossrefPubMedGoogle Scholar
• 54 Rabinowitz LO, Zaim MT. A clinicopathologic approach to granulomatous dermatoses. J Am Acad Dermatol 1996; 35 (04) 588-600
  CrossrefPubMedGoogle Scholar
• 55 Cardoso JC, Cravo M, Reis JP, Tellechea O. Cutaneous sarcoidosis: a histopathological study. J Eur Acad Dermatol Venereol 2009; 23 (06) 678-682
  CrossrefPubMedGoogle Scholar
• 56 Wanat KA, Rosenbach M. A practical approach to cutaneous sarcoidosis. Am J Clin Dermatol 2014; 15 (04) 283-297
  CrossrefPubMedGoogle Scholar
• 57 Ball NJ, Kho GT, Martinka M. The histologic spectrum of cutaneous sarcoidosis: a study of twenty-eight cases. J Cutan Pathol 2004; 31 (02) 160-168
  CrossrefPubMedGoogle Scholar
• 58 Callen JP. The presence of foreign bodies does not exclude the diagnosis of sarcoidosis. Arch Dermatol 2001; 137 (04) 485-486
  PubMedGoogle Scholar
• 59 Marcoval J, Mañá J, Moreno A, Gallego I, Fortuño Y, Peyrí J. Foreign bodies in granulomatous cutaneous lesions of patients with systemic sarcoidosis. Arch Dermatol 2001; 137 (04) 427-430
  PubMedGoogle Scholar
• 60 Judson MA. The diagnosis of sarcoidosis. Curr Opin Pulm Med 2019; 25 (05) 484-496
  CrossrefPubMedGoogle Scholar
• 61 Judson MA, Baughman RP. How many organs need to be involved to diagnose sarcoidosis?: An unanswered question that, hopefully, will become irrelevant. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31 (01) 6-7
  PubMedGoogle Scholar
• 62 Costabel U, Guzman J, Baughman RP. Systemic evaluation of a potential cutaneous sarcoidosis patient. Clin Dermatol 2007; 25 (03) 303-311
  CrossrefPubMedGoogle Scholar
• 63 Imadojemu S, Rosenbach M. Advances in inflammatory granulomatous skin diseases. Dermatol Clin 2019; 37 (01) 49-64
  CrossrefPubMedGoogle Scholar
• 64 Imadojemu S, Wanat KA, Noe M, English JC, Rosenbach M. Cutaneous sarcoidosis. In: Baughman RP, Valeyre D. , eds. Sarcoidosis, A Clinician's Guide. Elsevier; 2019: 127-144
  CrossrefGoogle Scholar
• 65 Doherty CB, Rosen T. Evidence-based therapy for cutaneous sarcoidosis. Drugs 2008; 68 (10) 1361-1383
  CrossrefPubMedGoogle Scholar
• 66 Khatri KA, Chotzen VA, Burrall BA. Lupus pernio: successful treatment with a potent topical corticosteroid. Arch Dermatol 1995; 131 (05) 617-618
  CrossrefPubMedGoogle Scholar
• 67 Green CM. Topical tacrolimus for the treatment of cutaneous sarcoidosis. Clin Exp Dermatol 2007; 32 (04) 457-458
  CrossrefPubMedGoogle Scholar
• 68 Katoh N, Mihara H, Yasuno H. Cutaneous sarcoidosis successfully treated with topical tacrolimus. Br J Dermatol 2002; 147 (01) 154-156
  CrossrefPubMedGoogle Scholar
• 69 Fredman R, Tenenhaus M. Cushing's syndrome after intralesional triamcinolone acetonide: a systematic review of the literature and multinational survey. Burns 2013; 39 (04) 549-557
  CrossrefPubMedGoogle Scholar
• 70 Gharavi N, Diehl J, Soriano T. Cutaneous sarcoidosis successfully treated with intralesional 5-fluorouracil. Dermatol Surg 2015; 41 (09) 1082-1085
  CrossrefPubMedGoogle Scholar
• 71 Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 2001; 137 (01) 69-73
  CrossrefPubMedGoogle Scholar
• 72 Steen T, English JC. Oral minocycline in treatment of cutaneous sarcoidosis. JAMA Dermatol 2013; 149 (06) 758-760
  CrossrefPubMedGoogle Scholar
• 73 Morse SI, Cohn ZA, Hirsch JG, Schaeder RW. The treatment of sarcoidosis with chloroquine. Am J Med 1961; 30: 779-784
  CrossrefPubMedGoogle Scholar
• 74 Siltzbach LE, Teirstein AS. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand Suppl 1964; 425: 302-308
  PubMedGoogle Scholar
• 75 Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol 1990; 23 (3, Pt 1): 487-489
  CrossrefPubMedGoogle Scholar
• 76 Zic JA, Horowitz DH, Arzubiaga C, King Jr LE. Treatment of cutaneous sarcoidosis with chloroquine. Review of the literature. Arch Dermatol 1991; 127 (07) 1034-1040
  CrossrefPubMedGoogle Scholar
• 77 Baughman RP, Judson MA, Ingledue R, Craft NL, Lower EE. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol 2012; 148 (02) 262-264
  CrossrefPubMedGoogle Scholar
• 78 Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155 (05) 1665-1669
  CrossrefPubMedGoogle Scholar
• 79 Nguyen YT, Dupuy A, Cordoliani F. , et al. Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol 2004; 50 (02) 235-241
  CrossrefPubMedGoogle Scholar
• 80 Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: a comprehensive review: a review of glucocorticoid pharmacology and bone health. J Am Acad Dermatol 2017; 76 (01) 1-9
  CrossrefPubMedGoogle Scholar
• 81 Veien NK, Brodthagen H. Cutaneous sarcoidosis treated with methotrexate. Br J Dermatol 1977; 97 (02) 213-216
  CrossrefPubMedGoogle Scholar
• 82 Lower EE, Baughman RP. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci 1990; 299 (03) 153-157
  CrossrefPubMedGoogle Scholar
• 83 Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995; 155 (08) 846-851
  CrossrefPubMedGoogle Scholar
• 84 Stagaki E, Mountford WK, Lackland DT, Judson MA. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest 2009; 135 (02) 468-476
  CrossrefPubMedGoogle Scholar
• 85 Tu J, Chan J. Cutaneous sarcoidosis and infliximab: evidence for efficacy in refractory disease. Australas J Dermatol 2014; 55 (04) 279-281
  CrossrefPubMedGoogle Scholar
• 86 Tuchinda P, Bremmer M, Gaspari AA. A case series of refractory cutaneous sarcoidosis successfully treated with infliximab. Dermatol Ther (Heidelb) 2012; 2 (01) 11
  CrossrefPubMedGoogle Scholar
• 87 Wanat KA, Rosenbach M. Case series demonstrating improvement in chronic cutaneous sarcoidosis following treatment with TNF inhibitors. Arch Dermatol 2012; 148 (09) 1097-1100
  CrossrefPubMedGoogle Scholar
• 88 Judson MA. Successful treatment of lupus pernio with adalimumab. Arch Dermatol 2011; 147 (11) 1332-1333
  CrossrefPubMedGoogle Scholar
• 89 Heffernan MP, Smith DI. Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol 2006; 142 (01) 17-19
  CrossrefPubMedGoogle Scholar
• 90 Baughman RP, Judson MA, Lower EE. , et al; Sarcoidosis Investigators. Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. Sarcoidosis Vasc Diffuse Lung Dis 2016; 32 (04) 289-295
  PubMedGoogle Scholar
• 91 Thielen AM, Barde C, Saurat JH, Laffitte E. Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists. Dermatology 2009; 219 (01) 59-62
  CrossrefPubMedGoogle Scholar
• 92 Dhaille F, Viseux V, Caudron A. , et al. Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases. Dermatology 2010; 220 (03) 234-237
  CrossrefPubMedGoogle Scholar
• 93 Ishiguro T, Takayanagi N, Kurashima K. , et al. Development of sarcoidosis during etanercept therapy. Intern Med 2008; 47 (11) 1021-1025
  CrossrefPubMedGoogle Scholar
• 94 González-López MA, Blanco R, González-Vela MC, Fernández-Llaca H, Rodríguez-Valverde V. Development of sarcoidosis during etanercept therapy. Arthritis Rheum 2006; 55 (05) 817-820
  CrossrefPubMedGoogle Scholar
• 95 Chiarchiaro J, Chen BB, Gibson KF. New molecular targets for the treatment of sarcoidosis. Curr Opin Pulm Med 2016; 22 (05) 515-521
  CrossrefPubMedGoogle Scholar
• 96 Damsky W, Thakral D, Mcgeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. J Am Acad Dermatol 2020; 82 (03) 612-621
  CrossrefPubMedGoogle Scholar
• 97 Judson MA, Baughman RP, Costabel U. , et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J 2014; 44 (05) 1296-1307
  CrossrefPubMedGoogle Scholar
• 98 Hornick N, Wang A, Lim Y. , et al. Development or worsening of sarcoidosis associated with IL-17 blockade for psoriasis. J Eur Acad Dermatol Venereol 2020 Doi: 10.1111/jdv.16451 [Epub ahead of print]
  PubMedGoogle Scholar
• 99 Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. N Engl J Med 2018; 379 (26) 2540-2546
  CrossrefPubMedGoogle Scholar
• 100 Damsky W, Young BD, Sloan B, Miller EJ, Obando JA, King B. Treatment of multiorgan sarcoidosis with tofacitinib. ACR Open Rheumatol 2020; 2 (02) 106-109
  CrossrefPubMedGoogle Scholar
• 101 Wei JJ, Kallenbach LR, Kreider M, Leung TH, Rosenbach M. Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera. JAAD Case Rep 2019; 5 (04) 360-361
  CrossrefPubMedGoogle Scholar
• 102 Damsky W, Singh K, Galan A, King B. Treatment of necrobiosis lipoidica with combination Janus kinase inhibition and intralesional corticosteroid. JAAD Case Rep 2020; 6 (02) 133-135
  CrossrefPubMedGoogle Scholar
• 103 Lee JJ, English III JC. Improvement in ulcerative necrobiosis lipoidica after Janus kinase-inhibitor therapy for polycythemia vera. JAMA Dermatol 2018; 154 (06) 733-734
  CrossrefPubMedGoogle Scholar
• 104 Damsky W, King BA. Treatment of granuloma annulare with tofacitinib 2% ointment. JAAD Case Rep 2019; 6 (01) 69-71
  CrossrefPubMedGoogle Scholar
• 105 Lamrock E, Brown P. Development of cutaneous sarcoidosis during treatment with tumour necrosis alpha factor antagonists. Australas J Dermatol 2012; 53 (04) e87-e90
  CrossrefPubMedGoogle Scholar
• 106 Le V, Crouser ED. Potential immunotherapies for sarcoidosis. Expert Opin Biol Ther 2018; 18 (04) 399-407
  CrossrefPubMedGoogle Scholar
• 107 Julian MW, Shao G, Schlesinger LS. , et al. Nicotine treatment improves Toll-like receptor 2 and Toll-like receptor 9 responsiveness in active pulmonary sarcoidosis. Chest 2013; 143 (02) 461-470
  CrossrefPubMedGoogle Scholar
• 108 Grunewald J, Grutters JC, Arkema EV, Saketkoo LA, Moller DR, Müller-Quernheim J. Sarcoidosis. Nat Rev Dis Primers 2019; 5 (01) 45
  CrossrefPubMedGoogle Scholar